Pds Biotechnology Corporation

The Scripps Research Institute

University Health Network

Weihsu Chen

Leaf Huang

Frank Bedu-Addo

James C Paulson

Kenya Johnson

Peter Zandstra

Gregory Conn

John Dick

Elizabeth Ann Vasievich

Kenya N Toney Johnson

Weili Yan

Corwin Nycholat

James Kennedy

Norihito Kawasaki

Stanley Ng

Jean Wang

Mark Minden

Amanda Mitchell

The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.

Stimulation of an immune response by cationic lipids

There is described herein a method of prognosing or classifying a subject with acute myeloid leukemia (AML) comprising: (a) determining the expression level of at least 3 genes in a test sample from the subject selected from the group consisting of DNMT3B, ZBTB46, NYNRIN, ARHGAP22, LAPTM4B, MMRN1, DPYSL3, KIAAQ125. CDK6, CPXM1, SOCS2, SMIM24, EMP1, NGFRAP1, CD34, AKR1C3, GPR56; and (b) comparing expression of the at least 3 genes in the test sample with reference expression levels of the at least 3 genes from control samples from a cohort of patients; wherein a difference or similarity in the expression of the at least 3 genes in the test sample and the reference expression levels is used to prognose or classify the subject with AML into a low risk group or a high risk group for worse survival.

Method for identifying high-risk AML patients

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in Ris a quaternary ammonium group, Yis a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, Rand Rare independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.

Stimulation of an immune response by enantiomers of cationic lipids

The present invention provides liposome targeting compounds for targeting cells expressing sialic acid binding Ig-like lectin (Siglec). The liposome compounds typically comprise a binding moiety that is a glycan ligand of the Siglec on the target cell. The liposome compounds also incorporate or encapsulate a biological agent (e.g., an antigen or a therapeutic agent) that can be delivered to the target cell to modulate or kill the target cell. The invention also provides methods of using the liposome targeting compounds for targeted delivery of antigen and for modulating immune cells or immune responses.

Liposome targeting compounds and related uses

Growing community of inventors

Toronto, Canada

Weihsu Chen